Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 60

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

24 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
25.08.2026journal-article

Cancer Science

Elucidating PI3K / AKT / PTEN Pathway Alterations at Single‐Cell Level in CTCs From HR +/ HER2 − Metastatic Breast Cancer

Tania Rossi, Michela Palleschi, Caterina Gianni, Filippo Merloni, Alessandra Virga, Sara Bandini, Davide Angeli, Michela Tebaldi, Roberta Maltoni, Paola Ulivi, Antonino Musolino

ABSTRACT Alterations in the PI3K signaling pathway are common in hormone receptor‐positive (HR+)/HER2‐negative metastatic breast cancer (MBC) and are associated with response to PI3K and AKT inhibitor‐targeted therapies. When metastasis biopsy is unavailable for genetic testing, circulating tumor DNA (ctDNA) analysis is an alternative strategy for tumor genotyping, but it is less sensitive for gain and loss analysis. Here, we assess molecular alterations of the genes of this axis— PIK3CA , AKT1 , and PTEN —in circu …

25.08.2026journal-article

Frontiers in Pharmacology

Identification of EGFR, MMP9, and AGTR1 as actionable therapeutic targets in acetyl tributyl citrate-driven breast cancer: integrated network toxicology and in vitro validation

Bo Zhou, Lisi Zhou, Yue Zhang, Xiangyang An

Background Growing exposure to acetyl tributyl citrate (ATBC) drives breast cancer (BC) progression and poses significant challenges to clinical management. However, the precise molecular targets that mediate ATBC-induced tumor progression remain largely elusive. Identifying these cell surface and intracellular targets is critical for the development of rational, integrated targeted therapeutic strategies. Methods A comprehensive Network Toxicology approach combined with multi-omics bioinformatics was employed to e …

25.08.2026journal-article

The Journal of Gene Medicine

CircFut8 Suppresses Bladder Cancer by Modulating SRSF9‐Dependent Pre‐mRNA Splicing

Weifeng Yang, Lv Yao, Lijun Wan, Changshui Zhuang

ABSTRACT Objective Circular RNAs (circRNAs) represent key regulators in cancer pathogenesis; however, their involvement in alternative splicing (AS) remains poorly understood. Methods Expression of circFut8 was detected in bladder cancer ( BC ) tissues/cell lines; RNA pull‐down, cross‐linking immunoprecipitation (CLIP) assays verified circFut8's interaction with splicing factor SRSF9. CircFut8 overexpression was performed to assess its effects on BC cell proliferation in vitro (CCK‐8, colony formation) and tumor gr …

25.08.2026journal-article

Applied Organometallic Chemistry

Half‐Sandwich p ‐Cymene Ruthenium (II) Complexes of N/S‐Donor Imine Ligands: Promising Chemotherapeutic Agent Against HCT116 Colon Cancer Cells

Basmah Abdulbaset Madkhali, Rais Ahmad Khan, Mohammad Abul Farah, Ibtisam I. BinSharfan, Wajhul Qamar, Waleed A. Q. Hailan, Khalid M. Al‐Anazi, Arman D. Hadi, Ali Alsalme

ABSTRACT Two half‐sandwich (η 6 ‐ p ‐cymene) ruthenium compounds, Ru‐CH₃L and Ru‐HL , have been prepared via metal–ligand coordination with ligands CH₃L and HL , respectively. The synthesized compounds were characterized by FT‐IR, 1 H NMR, 13 C NMR, and elemental analysis. The coordination of the ligand to Ru (II) via phenolic‐O and imine‐N atoms was proved by the single X‐ray structure of CH₃L , HL , and Ru‐CH₃L . Moreover, the interactions of Ru‐CH 3 L and Ru‐HL with HSA were also examined. Ru‐CH 3 L and Ru‐HL bi …

25.08.2026journal-article

MedComm – Oncology

TLR7 Agonist Nanomedicine Suppresses Lung Metastasis of Osteosarcoma by Remodeling the Immune Microenvironment

Xinyue Zhang, Hao Zeng, Furong Qin, Yuquan Wei, Dandan Wan, Xiawei Wei

ABSTRACT Osteosarcoma (OS) is an aggressive malignancy with high pulmonary metastatic potential, and effective therapies targeting metastasis and modulating the immunosuppressive tumor microenvironment are urgently needed. This study aimed to evaluate a TLR7 agonist liposome (1V209‐Cho‐Lip) for its anti‐metastatic effects and mechanisms in OS. In both the OS tail‐vein transplantation mouse model and orthotopic transplantation mouse model, 1V209‐Cho‐Lip significantly reduced the pulmonary metastatic burden and prolo …

25.08.2026journal-article

Annals of the American Thoracic Society

Language Preference Associated with Disparities in Annual Lung Cancer Screening Adherence in an Integrated Healthcare System

Eduardo R Núñez, Aruna Priya, Viswanathan Shankar, Rose Ganim, Lawrence N Benjamin, Lisa C Diamond, Penelope Pekow, Renda Soylemez Wiener, Peter K Lindenauer

Abstract Introduction Lung cancer screening (LCS) with annual low-dose CT reduces mortality, but benefit depends on timely adherence to annual screening. Language barriers may introduce additional challenges to screening adherence. We examined the association between non-English language preference and annual adherence to LCS. Methods We conducted a retrospective cohort study of LCS-eligible adults who underwent initial screening between January 1, 2015, and March 10, 2025, within a four-hospital regional health sy …

25.08.2026journal-article

Journal of Clinical Investigation

RhoA wild-type allele loss unleashes the cancer driver function of RhoA E40Q

Justine Noujarède, Qiuyue Wang, Eleftherios Panagiotis Kokkinogenis, Yuewan Luo, Ivona Cudina, Simon Willaume, Clémence Mooser, Lap Phuoc Nguyen, Mads Frederik Poulsen, Simon Heijmerikx, Thu Han Le Phan, Xiubin He, Jesper Bøje Andersen, Claus Storgaard Sørensen, Cord Brakebusch

Cancer hotspot mutations of unknown function often obscure the functional understanding of the molecular pathways underlying cancer formation and limit precision medicine progress. Here, we investigated unresolved driver functions of RHOA in head and neck squamous cell carcinoma (HNSCC). Our investigation reveals that RHOA E40Q is a partial loss-of-function allele which paradoxically promotes tumorigenesis only in the absence of wild-type RhoA. Therefore, mice expressing RHOA E40Q specifically in keratinocytes lack …

25.08.2026journal-article

JAMA

Cancer Medicine Approvals in the US

Brian Shkabari, Nicole I. Vorko, Wesley M. Geerlinks, Elizaveta Purh, Claire M. Diana-Gonsalves, Svasti Sutaria, Bishal Gyawali

This cross-sectional study examines trends in cancer medicine approvals by the US Food and Drug Administration (FDA) for adult solid tumors between 2006 and 2025, including both original and supplemental indication approvals.

25.08.2026journal-article

Cancers

Gastric Cancer Biomarkers: From Cellular Identity to Precision Oncology

Catalin-Bogdan Satala, Alina-Mihaela Gurau, Gabriela Patrichi, Gabriela Gurau, Roxana-Cristina Mehedinti, Daniela Mihalache

Gastric Cancer (GC) is characterized by remarkable biological heterogeneity, reflected by the continuous expansion of biomarkers with diagnostic, prognostic, predictive, and therapeutic relevance. However, most reviews organize these biomarkers according to signaling pathways or individual molecular alterations, often overlooking the interconnected biological processes and functional states that shape gastric carcinogenesis and tumor evolution. This review proposes a biology-oriented conceptual framework that inter …

25.08.2026journal-article

Frontiers in Oncology

The double-edged sword of SASP in breast cancer: from tumor suppression to progression and therapy resistance

Xianneng Gao, Yunlong Zhang, Yue Sun, Tiefeng Xu

The senescence-associated secretory phenotype (SASP) represents a complex and dynamic collection of bioactive factors secreted by senescent cells, which exerts dual regulatory effects on breast cancer (BC) progression. When SASP is transiently expressed, it promotes tumor suppression by recruiting immune cells to enhance immunosurveillance against senescent cells, and by transmitting paracrine signals that inhibit cancer cell proliferation. In contrast, when senescent cells cannot be cleared in a timely manner and …

25.08.2026journal-article

Biomedical Chromatography

Serum Pharmacochemistry Combined With Network Pharmacology to Explore Potential Bioactive Components and Mechanisms of Pomegranate Peel in the Treatment of Colorectal Cancer

Zainaipuguli Yisimayili, Guzilinuer Yimamu, Reziya Aimaiti, Maihesumu Aikemu, Kurexi Yunusi

ABSTRACT Pomegranate peel (PP) is a traditional Chinese medicinal material. PP has multiple biological activities such as anti‐inflammatory and anticancer activities. Although biological activity investigations of PP are growing, few studies have focused on its chemical constituents, and there is a lack of research on its in vivo metabolic characteristics. In this study, UHPLC‐Orbitrap Exploris‐MS was used to analyze constituents of PP and, for the first time, its metabolic profiles. Network pharmacology and molecu …

25.08.2026journal-article

Cells

Cytokine Regulation of the Bone Pre- and Metastatic Niches: Implications for Breast Cancer Dormancy

Tamara A. Clover, Maria L. Price, Lewis A. Quayle, Christine L. Le Maitre, Penelope D. Ottewell

Breast cancer relapse in bone is a significant clinical problem that is experienced in ~70–80% of patients with late-stage breast cancer. This condition commonly occurs 5–10+ years following surgical removal of the primary tumour. The long latency seen prior to relapse in bone is a result of tumour cell dormancy. Once disseminated to the bone, tumour cell interaction with the bone metastatic niche (endosteal niche and endovascular cells) maintains cells in a dormant state until changes to the local environment acti …

25.08.2026journal-article

Medical Sciences

Blood Transfusion in End-of-Life Cancer Care: Clinical Evidence, Patient Blood Management and Goal-Concordant Practice

Saikat Mandal, Manideepa Maji, Ashish Sharma, Arkadeep Dhali

Blood transfusion near the end of life for patients with cancer may relieve symptoms attributed to anaemia or control bleeding, but its palliative value depends on whether benefit occurs within the patient’s expected survival and outweighs the clinical and practical burden of treatment. This structured narrative review examines evidence concerning red-cell and platelet transfusion, transfusion-sparing patient blood management, hospice access and alternative delivery models in adults receiving palliative or end-of-l …

25.08.2026journal-article

Frontiers in Cancer Control and Society

Childhood cancer incidence, survival and mortality patterns in Argentina, 2000–2022: from the Argentine Oncopediatric Registry (ROHA)

Florencia Moreno, Maria Agustina Chaplin, Mariana Nana, María Graciela Abriata

Introduction Population-based cancer registries are essential tools for monitoring the burden of childhood cancer and guiding evidence-based public health policies. In pediatric oncology, long-term registry data are particularly valuable for evaluating survival trends, identifying inequities, and informing health system strengthening. The Argentina Oncopediatric Registry (ROHA), established in 2000, provides a unique framework for evaluating long-term trends in childhood cancer incidence, survival, and mortality. M …

25.08.2026journal-article

Clinical Case Reports

Rectal Gastrointestinal Stromal Tumor Poor Response to Imatinib: A Case Report

Majid Einakchi, Alireza Samimi, Tooraj Zandbaf, Narges Mesbah

ABSTRACT A 63‐year‐old man presented with persistent constipation lasting 6.5 months. Digital rectal examination revealed a soft‐tissue lesion near the anal verge without bleeding. Further evaluation identified a rectal mass. Treatment with imatinib for 6 months showed no significant response. The patient subsequently underwent surgical resection, with favorable short‐term clinical outcomes.

25.08.2026journal-article

Sağlık Bilimleri Dergisi

Prognostic Role of Gas6/sAXL Signaling Pathway in Predicting Treatment Resistance in Idiopathic Granulomatous Mastitis

Sedat Çarkıt, Merve Özel, Alper Bahadır Öz, Mustafa Gök, Alper Celal Akcan, Sevil Demiray, Hulya Akgun, Gülden Başkol, Mustafa Karaağaç, Gökmen Zararsız

Idiopathic granulomatous mastitis is a rare chronic inflammatory breast disease with unclear pathogenesis and unpredictable therapeutic outcomes. Although the Gas6/sAXL signaling pathway plays an important role in immune regulation, its prognostic significance in idiopathic granulomatous mastitis remains unknown. This retrospective observational cohort study included 37 women with histopathologically confirmed idiopathic granulomatous mastitis, categorized as treatment-responsive (n=18) or treatment-resistant (n=19 …

25.08.2026journal-article

Clinical Cancer Research

A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer

Scott T. Tagawa, Charlene Thomas, Abdul Baseet Arham, Aaron Holmes, Valentina Marulanda Corzo, Tobechukwu Okobi, Shankar Vallabhajosula, Vasilios Avlonitis, Sandra Huicochea Castellanos, Jones T. Nauseef, Elisabeth O’Dwyer, Maham Fatima, Peter Gregos, Sarah Yuan, Cora N. Sternberg, Ana Molina, David M. Nanus, Neil H. Bander, Joseph R. Osborne

Abstract Purpose: To test the safety of two regimens at differing levels of radioactivity of prostate-specific membrane antigen (PSMA)–targeted α-radionuclide 225Ac-J591. Patients and Methods: Patients with progressive, metastatic androgen pathway modulation–resistant prostate cancer were enrolled in two parallel dose-escalation cohorts: (i) fractionated-dose regimen (single cycle of 45–65 KBq/kg of 225Ac-J591 on days 1 and 15; main cohort agnostic to prior receipt of 177Lu-PSMA and an additional cohort with prior …

25.08.2026journal-article

The Oncologist

Bone health in advanced prostate cancer: pathophysiology and management strategies

Rana R McKay, Heather Hofflich, Gina Woods, Richard Andres, Azeez Farooki

Abstract Bone loss and bone metastases can increase morbidity and impair quality of life for patients with prostate cancer. Use of hormonal agents can compromise bone integrity from treatment initiation, and the emergence of bone metastases further increases the risk of symptomatic skeletal-related events. Management of bone health should therefore be pivotal across the prostate cancer continuum. Current guidelines recommend that all men starting or receiving androgen-deprivation therapy for prostate cancer be asse …

25.08.2026journal-article

Biotecnia

Ezrina regula la migración e invasión inducidas por leptina en las líneas celulares de cáncer de mama MDA-MB-231 y MCF-7

Arizbeth Guadalupe Villanueva Flores, Marinath Zacil Domínguez Adame, Lorena Cayetano Salazar, Juan Carlos Juárez-Cruz, Ana Elvira Zacapala Gómez, Adán Arizmendi Izazaga, Miguel Angel Mendoza Catalán

El cáncer de mama es una de las principales causas de muertepor cáncer en mujeres y su progresión depende, entreotros factores, de procesos celulares asociados a la migracióne invasión. La familia de proteínas ezrina-radixina-moesina(ERM) participa en la reorganización del citoesqueleto y lamotilidad celular; en particular, ezrina se ha implicado en etapasclave de progresión tumoral y metástasis. Por otro lado,estudios epidemiológicos y experimentales sugieren unarelación entre obesidad y progresión del cáncer de m …

25.08.2026journal-article

Journal of Cancer Education

Cross-Cultural Validation of the 11-Item Frommelt Attitude Toward the Care of the Dying Scale Among U.S. Preclinical Medical Students

Marco Miniotti, Barbara Loera, Giorgia Molinengo, Michael Lee, Amy Hayton, Julio Silvestre, Paolo Leombruni

Abstract Positive attitudes toward caring for dying patients are core competencies in medical education and particularly relevant to cancer education, where physicians must be prepared for communication, symptom management, and end-of-life decision-making. The Frommelt Attitude Toward the Care of the Dying (FATCOD) scale is widely used to assess these attitudes, yet the original 30-item version has shown psychometric limitations across cultures. This study examined the factorial structure and measurement properties …

25.08.2026journal-article

AIDS

Reframing analytical treatment interruption through participants’ and decliners’ eyes: insights from an HIV remission trial

Sarah Lefebvre, Cécile Goujard, Laurence Meyer, Christine Durier, Mélanie Jaudon, Joséphine Tine, Lucie De Gastines, Nicolas Leturque, Vincent Meiffredy, Bruno Spire, Asier Saez-Cirion, Christel Protiere

Objectives: This study explored how participants and decliners perceived the French ANRS-175-RHIVIERA-01 trial, which evaluated HIV control during analytical treatment interruption (ATI) among individuals treated with antiretroviral treatment (ART) since acute HIV infection, virologically suppressed, and carrying the HLA-B35/53Bw4TTC2 genotype. It also explored how participants’ experiences evolved over follow-up. Methods: Between 2023 and 2024, semi-structured interviews were conducted with decliners and participa …

25.08.2026journal-article

Journal of Surgical Oncology

Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes, Local Control, and Survival?

Dhruv J. Patel, Lauren M. Janczewski, Joseph H. Cotler, George Molina, Brett L. Ecker, David Bentrem, Shishir K. Maithel, Mohamed E. Abazeed, John P. Hayes, Bryan Palis, Amanda B. Francescatti, Ronald J. Weigel, Judy Boughey, Lesly Dossett, Akhil Chawla

ABSTRACT Objectives Neoadjuvant chemoradiation for PDAC with vascular invasion remains understudied. The aim of this study is to compare neoadjuvant chemotherapy with chemoradiation (NAC + CRT) versus neoadjuvant chemotherapy (NAC) for PDAC with vascular involvement. Methods The National Cancer Database was reviewed between 2018 and 2023, including patients with T4 PDAC initiating NAC or NAC + CRT. The primary outcome of overall survival (OS) was examined among unresected and resected cohorts. Secondary outcomes in …

25.08.2026journal-article

Discover Oncology

Exploratory analysis of a novel obesity-related gene-based prognostic model as a potential prognostic biomarker in multiple myeloma

Haoyuan Hong, Yingying Qin, Gengyang Lin, Meiwei Li, Qingyuan Xu, Houming Kan, Lei Jiang, Bin Luo

Abstract Background This study aimed to elucidate the genetic interplay between obesity and multiple myeloma (MM) and to develop a novel obesity-related gene-based prognostic model using an integrated multi-omics framework combining single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq). Methods A differential expression analysis of the GSE132604 exploratory discovery cohort was performed using the limma package to identify obesity-related differentially expressed genes (DEGs). Weighted gene co-ex …

25.08.2026journal-article

The Oncologist

Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study

Fabiola Giudici, Diego Serraino, Fabio Puglisi, Samuele Massarut, Lorenzo Gerratana, Serena Scomersi, Federica Toffolutti, Ettore Bidoli, Luigino Dal Maso, Friuli Venezia Giulia Cancer Registry working group, Tiziana Angelin, Emilia De Santis, Ornella Forgiarini, Elodie Lazzaretto, Mariella Losciale, Martina Taborelli

Abstract Background Stage at diagnosis, histologic grade, and molecular subtypes are established prognostic indicators for women with breast cancer (BC), but their impact on population-based survival estimates is poorly documented. This study assessed long-term BC survival trends according to these factors. Methods We identified women aged <75 years diagnosed with stage I-IV invasive BC between 2004 and 2014 from the Friuli Venezia Giulia (North Eastern Italy) Cancer Registry (N = 10,476). Follow-up through 2023 …